GlycoMimetics announced plans to initiate a clinical trial of GMI-1359 in breast cancer patients whose tumors have spread to bone. GMI-1359 is a dual function antagonist that targets both E-selectin and CXCR4, both of which are involved in tumor trafficking and metastatic spread. The trial will evaluate dose escalation as well as safety and pharmacodynamic markers in these patients. GlycoMimetics expects to initiate this trial in the second half of 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.